Cargando…

Multiple myeloma : risk factors, diagnosis, and treatments /

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of monoclonal immunoglobulin-secreting plasma cells in the bone marrow (BM). MM is associated with lytic bone lesions, anemia, immunodeficiency, and renal impairment. Multiple myeloma accounts for more than 10%...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Holt, Steve (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Nova Biomedical, [2014]
Colección:Cancer etiology, diagnosis, and treatments.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 EBSCO_ocn893207743
003 OCoLC
005 20231017213018.0
006 m o d
007 cr cnu---unuuu
008 141017s2014 gw o 000 0 eng d
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d OCLCF  |d D6H  |d AGLDB  |d YDX  |d OCLCQ  |d VTS  |d STF  |d M8D  |d VLY  |d OCLCO  |d OCLCQ 
020 |a 9781633215474  |q (electronic bk.) 
020 |a 1633215474  |q (electronic bk.) 
029 1 |a AU@  |b 000065475558 
029 1 |a DEBBG  |b BV043783133 
029 1 |a DEBSZ  |b 472849549 
035 |a (OCoLC)893207743 
050 4 |a RC280.B6 
072 7 |a HEA  |x 039000  |2 bisacsh 
072 7 |a MED  |x 014000  |2 bisacsh 
072 7 |a MED  |x 022000  |2 bisacsh 
072 7 |a MED  |x 112000  |2 bisacsh 
072 7 |a MED  |x 045000  |2 bisacsh 
082 0 4 |a 616.99/418  |2 23 
049 |a UAMI 
245 0 0 |a Multiple myeloma :  |b risk factors, diagnosis, and treatments /  |c Steve Holt, editor. 
264 1 |a New York :  |b Nova Biomedical,  |c [2014] 
264 4 |c ©2014 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Cancer etiology, diagnosis and treatments 
588 0 |a Online resource; title from PDF title page (EBSCO, viewed October 17, 2014). 
505 0 |a MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS -- MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1: Recent Advances in Diagnosis and Treatment of Multiple Myeloma -- Abstract -- Introduction -- Current Therapies for Newly Diagnosed MM -- Novel Targeted Therapies for MM -- Conclusion -- Acknowledgment -- References -- Chapter 2: Development of Proteasome Inhibitors for the Treatment of Multiple Myeloma -- Abstract -- Introduction 
505 8 |a Ubiquitin-Dependent ProteolysisProteasome Inhibitors -- Bortezomib -- Bortezomib in Preclinical Studies on Human Myeloma Cell Lines and Primary Patient Multiple Myeloma Cells -- Bortezomib in Relapsed and/or Refractory Multiple Myeloma -- Clinical Studies -- The Second-Generation Proteasome Inhibitors with More Potency and Fewer Side-Effects Studied in Multiple Myeloma -- Conclusion and Perspectives -- Acknowledgments -- References 
505 8 |a Chapter 3: Cereblon as the Cellular Target Responsible for the Anti-Multiple Myeloma Activity of Immunomodulatory Drugs (Thalidomide, Lenalidomide and Pomalidomide)Abstract -- Introduction -- Cereblon and Its Role in Memory and Learning -- Cereblon as a Negative Modulator of the Adenosine Monophosphate-Activated Protein Kinase (AMPK) -- Immunomodulatory Drugs -- Mechanism of Immunomodulatory Drugs Action in the Treatment of Multiple Myeloma -- Immunomodulatory Activities of IMiDs -- Anti-Angiogenic Properties of IMiDs 
505 8 |a Inhibition of Cell Cycle and Induction of Apoptosis by IMiDsDisruption of Bone Marrow Stromal Support for Malignant MM Cells -- Effect of IMiDs on Myeloma Cell Proliferation -- Cereblon as the Direct Target Protein of IMiDs -- Cereblon as a Primary Target for Thalidomide Teratogenicity -- The Role of Ikaros Family Proteins in IMiDs and CRBN Mechanism -- Measurement of Cereblon mRNA and Cereblon Protein Levels as Biomarkers for IMiDs Response -- Conclusion and Perspectives -- Acknowledgments -- References 
505 8 |a Chapter 4: Review of Risk Factors, Diagnosis Criteria and Treatment in Multiple MyelomaAbstract -- Introduction -- Risk Factors -- Diagnosis -- Treatment -- When Should Treatment Be Started? -- Choice Initial Drug Therapy -- Transplantation -- Consolidation and Maintenance Therapy After Transplantation -- Treatment Options for Unfit Patient -- References -- Chapter 5: Diagnosis and Management of Oral Manifestations of Multiple Myeloma -- Abstract -- 1. Incidence and Case Series -- 2. Clinical Diagnosis -- 3. Diagnostic Imaging 
520 |a Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of monoclonal immunoglobulin-secreting plasma cells in the bone marrow (BM). MM is associated with lytic bone lesions, anemia, immunodeficiency, and renal impairment. Multiple myeloma accounts for more than 10% of all hematologic malignancies and about 1% of all cancers. Multiple myeloma remains mostly incurable despite conventional intensive high dose chemotherapy followed by hematopoietic stem cell transplant. The costs associated with multiple myeloma are among the highest. This book discusses the diag. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Multiple myeloma. 
650 2 |a Multiple Myeloma 
650 6 |a Myélome multiple. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x General.  |2 bisacsh 
650 7 |a MEDICAL  |x Clinical Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Diseases.  |2 bisacsh 
650 7 |a MEDICAL  |x Evidence-Based Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Internal Medicine.  |2 bisacsh 
650 7 |a Multiple myeloma.  |2 fast  |0 (OCoLC)fst01028990 
700 1 |a Holt, Steve,  |e editor. 
830 0 |a Cancer etiology, diagnosis, and treatments. 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=863035  |z Texto completo 
938 |a EBSCOhost  |b EBSC  |n 863035 
938 |a YBP Library Services  |b YANK  |n 12112089 
994 |a 92  |b IZTAP